What is the recommended management strategy for decompensated heart failure?

Treatment Summary for Decompensated Heart Failure

Intravenous loop diuretics are the cornerstone of therapy for decompensated heart failure, with initial dosing at 20-40 mg IV furosemide (or equivalent) for diuretic-naïve patients, or at least equivalent to the home oral dose for those already on diuretics, administered as either intermittent boluses or continuous infusion with close monitoring of symptoms, urine output, renal function, and electrolytes. 1

Initial Assessment and Diagnosis

• Measure natriuretic peptides (BNP, NT-proBNP, or MR-proANP) in all patients with acute dyspnea to differentiate acute heart failure from non-cardiac causes 1
• Assess hemodynamic profile early: Determine volume status (congestion), adequacy of perfusion, and blood pressure to guide therapy 1
• Obtain ECG and echocardiography immediately if cardiogenic shock is suspected 1
• Check cardiac troponins to identify acute coronary syndrome as a precipitating factor 1

Diuretic Therapy (First-Line Treatment)

Dosing Strategy

• For new-onset acute heart failure or patients not on oral diuretics: Start with 20-40 mg IV furosemide (or equivalent) 1
• For patients on chronic diuretic therapy: Initial IV dose should be at least equivalent to their oral daily dose 1
• Administration method: Either intermittent boluses or continuous infusion are acceptable; adjust dose and duration based on clinical response 1

Monitoring Diuretic Response

• Assess spot urine sodium at 2 hours post-diuretic: A level <50-70 mEq/L indicates inadequate response requiring dose escalation 1, 2
• Monitor urine output: Target >100-150 mL/hour in first 6 hours or 3-5 L in 24 hours 1, 2
• Daily weight monitoring: Aim for 0.5-1.5 kg weight loss in 24 hours 2
• Regular monitoring required: Symptoms, urine output, renal function, and electrolytes throughout IV diuretic use 1

Escalation for Diuretic Resistance

• Increase loop diuretic dose if initial response inadequate 1
• Add thiazide-type diuretic (e.g., metolazone) or spironolactone for refractory congestion 1, 2
• Consider acetazolamide as adjunctive therapy if congestion persists after maximizing loop diuretics over 24-48 hours 2
• Ultrafiltration may be considered for patients with obvious volume overload or refractory congestion not responding to medical therapy 1

Vasodilator Therapy

• IV vasodilators (nitroglycerin, nitroprusside, or nesiritide) should be considered for symptomatic relief in patients with systolic blood pressure >90 mmHg without symptomatic hypotension 1
• In hypertensive acute heart failure, IV vasodilators should be considered as initial therapy to improve symptoms and reduce congestion 1
• Monitor blood pressure and symptoms frequently during vasodilator administration 1
• For acute coronary syndrome or flash pulmonary edema: Nitroglycerin is preferred 1, 3

Respiratory Support

• Non-invasive positive pressure ventilation (CPAP or PS-PEEP) reduces respiratory distress and may decrease intubation rates 1
• CPAP is feasible in pre-hospital settings due to simplicity and minimal training requirements 1
• PS-PEEP is preferred on hospital arrival for patients with persistent respiratory distress, especially with acidosis, hypercapnia, or COPD history 1
• Increase FiO₂ up to 100% if necessary according to SpO₂, but avoid hyperoxia 1

Inotropic Support (Restricted Use)

Inotropic agents are NOT recommended unless the patient is symptomatically hypotensive or hypoperfused, due to safety concerns. 1

When Inotropes Are Considered

• Short-term IV infusion may be considered in patients with hypotension (SBP <90 mmHg) and/or signs of hypoperfusion to maintain systemic perfusion and end-organ function 1
• Options include: Dobutamine, dopamine, levosimendan, or phosphodiesterase III inhibitors 1
• Levosimendan or PDE III inhibitors may be considered to reverse beta-blockade effects if contributing to hypotension with hypoperfusion 1
• Vasopressors (norepinephrine preferably) may be considered in cardiogenic shock despite inotrope treatment 1
• Continuous ECG and blood pressure monitoring required due to risks of arrhythmia, myocardial ischemia, and hypotension 1

Continuation of Guideline-Directed Medical Therapy (GDMT)

In patients with worsening chronic HFrEF, every attempt should be made to continue evidence-based disease-modifying therapies in the absence of hemodynamic instability or contraindications. 1

• Continue beta-blockers, ACE inhibitors/ARBs, and mineralocorticoid receptor antagonists unless hemodynamically unstable 1
• Do not routinely discontinue GDMT for mild renal function decrease or asymptomatic blood pressure reduction during hospitalization 1
• Initiate GDMT during hospitalization after clinical stability is achieved in newly diagnosed HFrEF 1
• Beta-blockers should be continued or reduced in dose at admission but not typically held 4

Cardiogenic Shock Management

• Rapidly transfer to tertiary care center with 24/7 cardiac catheterization and ICU/CCU with mechanical circulatory support availability 1
• Immediate ECG and echocardiography are mandatory 1
• Consider urgent cardiac catheterization and revascularization in patients with ACS and signs of inadequate systemic perfusion 1

Additional Supportive Measures

• Thromboembolism prophylaxis (e.g., LMWH) is recommended in patients not already anticoagulated and without contraindications 1
• Identify and treat precipitating factors: ACS, uncontrolled hypertension, arrhythmias, infections, medication non-adherence, anemia, thyroid dysfunction 1
• Avoid medications that worsen heart failure: NSAIDs, COX-2 inhibitors, thiazolidinediones 1

Common Pitfalls to Avoid

• Do not use inotropes in normotensive patients without evidence of decreased organ perfusion 1
• Avoid routine invasive hemodynamic monitoring in normotensive patients responding to diuretics and vasodilators 1
• Do not discontinue GDMT prematurely for minor changes in blood pressure or renal function 1
• Recognize that midazolam is preferred over propofol for sedation due to fewer cardiac side effects 1